Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study

MT Newswires Live11:33

Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple prior treatments, according to a Hong Kong bourse filing Tuesday.

Of the 58 patients who could be assessed for tumor response, 34.5% had a confirmed objective response rate, indicating their cancer shrank or disappeared.

Meanwhile, the disease control rate, a measure of patients whose cancer shrank or stabilized after treatment, stood at nearly 88%.

The firm said it would present the data at the American Society of Clinical Oncology Genitourinary Cancers Symposium 2026.

Shares of the company were down nearly 3% in recent morning trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613763897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613763897","market":"us","top_or_hot":-1,"title":"Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study","media":"MT Newswires Live","content":"<html><body><p> Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple prior treatments, according to a Hong Kong bourse filing Tuesday.</p><p>Of the 58 patients who could be assessed for tumor response, 34.5% had a confirmed objective response rate, indicating their cancer shrank or disappeared.</p><p>Meanwhile, the disease control rate, a measure of patients whose cancer shrank or stabilized after treatment, stood at nearly 88%.</p><p>The firm said it would present the data at the American Society of Clinical Oncology Genitourinary Cancers Symposium 2026.</p><p>Shares of the company were down nearly 3% in recent morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDuality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-24 11:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple prior treatments, according to a Hong Kong bourse filing Tuesday.</p><p>Of the 58 patients who could be assessed for tumor response, 34.5% had a confirmed objective response rate, indicating their cancer shrank or disappeared.</p><p>Meanwhile, the disease control rate, a measure of patients whose cancer shrank or stabilized after treatment, stood at nearly 88%.</p><p>The firm said it would present the data at the American Society of Clinical Oncology Genitourinary Cancers Symposium 2026.</p><p>Shares of the company were down nearly 3% in recent morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4552","symbol_name":"Archegos爆仓风波概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2613763897","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613763897","pubTimestamp":1771904032,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4552":"Archegos爆仓风波概念","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK4118":"综合性资本市场","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","SSI":"Stage Stores Inc","BK4585":"ETF&股票定投概念","BK4566":"资本集团","09606":"映恩生物-B","BK4588":"碎股","DB":"德意志银行","BK1161":"生物科技","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC"},"translate_title":"Duality Biotherapeutics表示DB-1311在早期前列腺癌研究中显示出活性迹象","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1.5,"DB":1.5,"09606":1},"content_text":"Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple prior treatments, according to a Hong Kong bourse filing Tuesday.Of the 58 patients who could be assessed for tumor response, 34.5% had a confirmed objective response rate, indicating their cancer shrank or disappeared.Meanwhile, the disease control rate, a measure of patients whose cancer shrank or stabilized after treatment, stood at nearly 88%.The firm said it would present the data at the American Society of Clinical Oncology Genitourinary Cancers Symposium 2026.Shares of the company were down nearly 3% in recent morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613763897","isCrawlerRequest":true}